Skip to main content
. Author manuscript; available in PMC: 2019 Apr 3.
Published in final edited form as: Adv Cancer Res. 2018 Jun 9;140:295–325. doi: 10.1016/bs.acr.2018.04.015

Figure 3. Pharmacokinetics of ABC294640 in humans.

Figure 3

Top Panel. Plasma was isolated from patients given 500 mg of ABC294640 on either Day 1 or Day 28 of Cycle 1 and levels of ABC294640 were quantified using a GLP LC/MS method. Values represent the mean ± SEM for 7 data sets. Antitumor activity in mouse models occurs at ABC294640 doses ≥ 25 mg/kg, which provides plasma Cmax levels of 9 µM. The horizontal line indicates the Cmax predicted to have antitumor activity based on the mouse tumor models. Bottom Panel. Cmax values are shown for patient samples collected on either Day 1 or Day 28 (there is no change in Cmax or AUC in this period). The horizontal line indicates the Cmax predicted to have antitumor activity based on the mouse tumor models.